Business Standard

Biocon-Mylan launch insulin Glargine at lowest price in US market

The commercialisation in the US of the drug, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of $1 billion in sales through its biologics division by FY22

Biocon likely to channelise investments towards non-insulin biologics

Biocon has been expanding affordable access to biosimilar insulins to patients in Japan, Australia, Europe, India and key emerging markets

Samreen Ahmad Bengaluru
Biotechnology major Biocon’s subsidiary Biocon Biologics and partner Mylan have launched insulin glargine injection, under the brand name Semglee, in the US market, said the Bengaluru-based company on Monday. 

Biocon Biologics India and Mylan have launched the product in vial and pre-filled pen presentations in the US, Biocon said. It is approved to help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2 diabetes. Mylan, which is responsible for commercialisation in the US, would offer Semglee at a wholesale cost of $147.98 per package of five 3ml pens and $98.65 per 10ml vial, making

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 31 2020 | 9:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to